Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Klein O, Kee D, Gao B, Markman B, da Gama Duarte J, Quigley L, Jackett L, Linklater R, Strickland A, Scott C, Mileshkin L, Palmer J, Carlino M, Behren A, Cebon J. Klein O, et al. Among authors: scott c. J Immunother Cancer. 2021 Nov;9(11):e003156. doi: 10.1136/jitc-2021-003156. J Immunother Cancer. 2021. PMID: 34782426 Free PMC article. Clinical Trial.
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Lee CK, et al. Among authors: scott c. Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17. Br J Cancer. 2019. PMID: 30655615 Free PMC article. Clinical Trial.
RAF1 rearrangements are common in pancreatic acinar cell carcinomas.
Prall OWJ, Nastevski V, Xu H, McEvoy CRE, Vissers JHA, Byrne DJ, Takano E, Yerneni S, Ellis S, Green T, Mitchell CA, Murray WK, Scott CL, Grimmond SM, Hofmann O, Papenfuss A, Kee D, Fellowes A, Brown IS, Miller G, Kumarasinghe MP, Perren A, Nahm CB, Mittal A, Samra J, Ahadi M, Fox SB, Chou A, Gill AJ. Prall OWJ, et al. Mod Pathol. 2020 Sep;33(9):1811-1821. doi: 10.1038/s41379-020-0545-9. Mod Pathol. 2020. PMID: 32358589 Free article.
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J. Klein O, et al. Among authors: scott c. Clin Cancer Res. 2020 Sep 1;26(17):4454-4459. doi: 10.1158/1078-0432.CCR-20-0621. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532787 Clinical Trial.
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes.
Tohidi-Esfahani I, Warden A, Malunis E, DeNardis PL, Haurat J, Black M, Opat S, Kee D, D'Sa S, Kersten MJ, Spearing RL, Palomba ML, Olszewski AJ, Harrington C, Scott CL, Trotman J. Tohidi-Esfahani I, et al. Among authors: scott cl. Am J Hematol. 2021 Jun 1;96(6):E218-E222. doi: 10.1002/ajh.26173. Epub 2021 Apr 9. Am J Hematol. 2021. PMID: 33755232 Free article. No abstract available.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Nesic K, et al. Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. Cancer Res. 2021. PMID: 34321239
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Matulonis UA, et al. Among authors: scott c. Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8. Cancer. 2016. PMID: 27062051 Free article. Clinical Trial.
4,329 results